Action against Respondent, a pharmaceutical company, for alleged violation of interim financial review requirements of Regulation S-X.  According to the SEC, Respondent filed three Forms 10-Q that included financial statements that had not been reviewed by an independent public accounting firm.  Respondent has agreed to a cease-and-desist order.  The SEC did not impose a civil penalty based on Respondent’s demonstrated inability to pay.

SEC Order